NCT07375225Recruiting
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 21 Jan 2026
- Start date
- 1 Dec 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Federico II University
- NCT number
- NCT07375225
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 1 Dec 2024 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \< 18 years o \> 80 years;
Other
- Patients who refuse to participate and to sign informed consent.
Who the study is looking for
- \- Patients under alirocumab 300mg treatment.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Federico II University of Naples, Department of Advanced Biomedical Sciences Coordinator of this site? Confirm its status | Naples | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.